US Stock MarketDetailed Quotes
CYTK Cytokinetics
- 52.220
- +0.200+0.38%
Close Nov 27 16:00 ET
- 52.220
- 0.0000.00%
Post 16:02 ET
6.16BMarket Cap-9706P/E (TTM)
52.840High51.660Low792.66KVolume52.030Open52.020Pre Close41.44MTurnover0.68%Turnover RatioLossP/E (Static)118.01MShares110.25052wk High-442.54P/B6.13BFloat Cap32.50052wk Low--Dividend TTM117.41MShs Float110.250Historical High--Div YieldTTM2.27%Amplitude3.050Historical Low52.280Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Cytokinetics Stock Forum
Cytokinetics (CYTK) and Bayer have established an exclusive licensing agreement for aficamten in Japan, focusing on treating hypertrophic cardiomyopathy (HCM). The deal includes an upfront payment of €50 million to Cytokinetics, with potential additional earnings of €90 million in milestones through commercial launch (including €20 million near-term) and up to €490 million in commercial milestone payments. The collaboration involves tiered royalties on Japanese sales and ...
Baird upgraded Starbucks $Starbucks (SBUX.US)$ to Outperform from Neutral with a price target of $110, up from $81. The firm sees a more favorable risk/reward on Starbucks shares following the hiring of Brian Niccol as CEO.
Barclays upgraded Dell Technologies $Dell Technologies (DELL.US)$ to Equal Weight from Underweight with an unchanged price target of $97. The firm says much of the artificial intelligence "hype" ...
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...
This new thing I'm trying will be some random thoughts about the market. How to use some features on moomoo (a request by some) to do research and develop trading levels. To show this I will introduce some stocks iam in or will be starting positions in.
...
No comment yet